• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单次给药后流感病毒载量及帕拉米韦动力学,以及针对耐药变异株的帕拉米韦给药方案建议

Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.

作者信息

Sato Masatoki, Ito Masaki, Suzuki Shigeo, Sakuma Hiroko, Takeyama Aya, Oda Shinichi, Watanabe Masahiro, Hashimoto Koichi, Miyazaki Kyohei, Kawasaki Yukihiko, Hosoya Mitsuaki

机构信息

Department of Pediatrics, Fukushima Medical University, Fukushima, Japan

Department of Pediatrics, Soma General Hospital, Soma, Japan.

出版信息

Antimicrob Agents Chemother. 2015 Mar;59(3):1643-9. doi: 10.1128/AAC.04263-14. Epub 2014 Dec 29.

DOI:10.1128/AAC.04263-14
PMID:25547357
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4325767/
Abstract

We estimated the efficacy of the current single administration of peramivir on the basis of peramivir pharmacokinetics in the upper respiratory tract (URT) and determined the predictive peramivir concentration-time curve to assess its efficacy against viruses with decreased susceptibility to neuraminidase inhibitors. Serum, nasal swab, or aspiration samples were collected from 28 patients treated with 10 mg/kg body weight peramivir. The sequential influenza viral RNA load and susceptibility after peramivir administration were measured using a quantitative real-time reverse transcription-PCR and neuraminidase inhibition assay. The peramivir concentrations in the serum and URT after a single administration at 10 mg/kg were measured, and the predictive blood and URT peramivir concentration-time curves were determined to assess various administration regimens against resistant variants. The peramivir concentration decreased to <0.1% of the maximum concentration of drug in serum (Cmax) at 24 h after administration. Rapid elimination of peramivir from the URT by 48 h after administration may contribute to an increase in the influenza A viral load after day 3 but not to a decrease in the influenza B viral load, despite the absence of a decrease in the susceptibility to peramivir. A longer maintenance of a high level of peramivir in the URT is expected by divided administration rather than once-daily administration. When no clinical improvement is observed in patients with normal susceptibility influenza A and B, peramivir readministration should be considered. In severe cases caused by resistant variants, better inhibitory effectiveness and less frequent adverse events are expected by divided administration rather than once-daily administration with an increased dosage.

摘要

我们根据帕拉米韦在上呼吸道(URT)中的药代动力学,评估了当前单次使用帕拉米韦的疗效,并确定了预测性的帕拉米韦浓度-时间曲线,以评估其对神经氨酸酶抑制剂敏感性降低的病毒的疗效。从28例接受10mg/kg体重帕拉米韦治疗的患者中采集血清、鼻拭子或抽吸样本。使用定量实时逆转录PCR和神经氨酸酶抑制试验测量帕拉米韦给药后流感病毒RNA载量和敏感性的变化。测量了10mg/kg单次给药后血清和URT中的帕拉米韦浓度,并确定了预测性的血液和URT帕拉米韦浓度-时间曲线,以评估针对耐药变异体的各种给药方案。给药后24小时,帕拉米韦浓度降至血清中药物最大浓度(Cmax)的<0.1%。给药后48小时,帕拉米韦从URT中快速消除,这可能导致第3天后甲型流感病毒载量增加,但不会导致乙型流感病毒载量下降,尽管对帕拉米韦的敏感性没有降低。与每日一次给药相比,分次给药有望在URT中更长时间维持高水平的帕拉米韦。对于甲型和乙型流感病毒敏感性正常但无临床改善的患者,应考虑重新使用帕拉米韦。在由耐药变异体引起的严重病例中,与增加剂量的每日一次给药相比,分次给药有望获得更好的抑制效果和更少的不良事件。

相似文献

1
Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.单次给药后流感病毒载量及帕拉米韦动力学,以及针对耐药变异株的帕拉米韦给药方案建议
Antimicrob Agents Chemother. 2015 Mar;59(3):1643-9. doi: 10.1128/AAC.04263-14. Epub 2014 Dec 29.
2
Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.静脉注射流感病毒神经氨酸酶抑制剂帕拉米韦在健康日本受试者中的药代动力学和安全性。
Antivir Ther. 2017;22(4):313-323. doi: 10.3851/IMP3104. Epub 2016 Nov 2.
3
Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.静脉滴注帕拉米韦治疗儿童 2009 年甲型 H1N1 流感病毒感染的疗效、安全性和药代动力学。
Antimicrob Agents Chemother. 2012 Jan;56(1):369-77. doi: 10.1128/AAC.00132-11. Epub 2011 Oct 24.
4
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.口服神经氨酸酶抑制剂帕拉米韦在实验性人类流感中的疗效和耐受性:预防和治疗的随机对照试验
Antivir Ther. 2005;10(8):901-10.
5
Peramivir clearance in continuous renal replacement therapy.连续性肾脏替代治疗中帕拉米韦的清除率
Hemodial Int. 2010 Jul;14(3):339-40. doi: 10.1111/j.1542-4758.2010.00451.x. Epub 2010 May 18.
6
Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.帕拉米韦治疗甲型和乙型流感病毒感染:药代动力学病例系列。
Pharmacotherapy. 2019 Nov;39(11):1060-1065. doi: 10.1002/phar.2330. Epub 2019 Oct 4.
7
Optimizing antiviral therapy for influenza: understanding the evidence.优化流感抗病毒治疗:理解相关证据
Expert Rev Anti Infect Ther. 2015 Apr;13(4):417-25. doi: 10.1586/14787210.2015.1018183. Epub 2015 Feb 19.
8
Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.肌肉注射神经氨酸酶抑制剂帕拉米韦对小鼠体内致死性H5N1流感病毒有效。
Antiviral Res. 2008 Nov;80(2):150-7. doi: 10.1016/j.antiviral.2008.05.012. Epub 2008 Jun 23.
9
Immune response after a single intravenous peramivir administration in children with influenza.流感患儿单次静脉注射帕拉米韦后的免疫反应。
Antivir Ther. 2018;23(5):435-441. doi: 10.3851/IMP3222.
10
Peramivir for the treatment of influenza.帕拉米韦治疗流感。
Expert Rev Anti Infect Ther. 2012 Feb;10(2):123-43. doi: 10.1586/eri.11.174.

引用本文的文献

1
Pharmacologic background and clinical issue of anti-influenza drugs.抗流感药物的药理背景与临床问题
Fukushima J Med Sci. 2025 Jan 18;71(1):1-12. doi: 10.5387/fms.24-00029. Epub 2024 Dec 18.
2
Population analysis of oseltamivir-resistant variants for the rapid prediction of drug susceptibility by real-time reverse transcription polymerase chain reaction.实时逆转录聚合酶链反应快速预测药物敏感性的奥司他韦耐药变异体的人群分析。
Fukushima J Med Sci. 2022 Dec 21;68(3):153-159. doi: 10.5387/fms.2022-15. Epub 2022 Aug 31.
3
Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus' Susceptibility to E119V-Substituted Peramivir-Neuraminidase Complex.禽流感 H7N9 病毒对 E119V 取代帕拉米韦-神经氨酸酶复合物易感性的分子间机制和动态研究。
Molecules. 2022 Mar 2;27(5):1640. doi: 10.3390/molecules27051640.
4
Japanese Surveillance Systems and Treatment for Influenza.日本的流感监测系统与治疗
Curr Treat Options Infect Dis. 2016;8(4):311-328. doi: 10.1007/s40506-016-0085-5. Epub 2016 Oct 10.
5
Peramivir injection in the treatment of acute influenza: a review of the literature.帕拉米韦注射液治疗急性流感:文献综述
Infect Drug Resist. 2016 Aug 22;9:201-14. doi: 10.2147/IDR.S86460. eCollection 2016.
6
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.会议报告:第四届国际流感病毒研究与疫苗协会抗病毒小组会议:流感及其他呼吸道病毒的新型抗病毒疗法
Antiviral Res. 2016 May;129:21-38. doi: 10.1016/j.antiviral.2016.01.012. Epub 2016 Feb 9.

本文引用的文献

1
Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.奥司他韦和扎那米韦治疗儿童的流感 B 病毒载量和敏感性的顺序变化。
Pediatr Infect Dis J. 2014 Jul;33(7):e168-72. doi: 10.1097/INF.0000000000000266.
2
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.日本 2013 年 11 月至 12 月出现的具有交叉耐药性的甲型 H1N1pdm09 流感病毒社区集群
Euro Surveill. 2014 Jan 9;19(1):20666. doi: 10.2807/1560-7917.es2014.19.1.20666.
3
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.2011-2012 年美国流行的流感病毒的药物敏感性监测:世卫组织抗病毒工作组标准的应用。
Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215. Epub 2013 Dec 2.
4
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.R292K 取代与流感 A(H7N9)病毒的药物敏感性。
Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.
5
Clinical findings in 111 cases of influenza A (H7N9) virus infection.111 例甲型 H7N9 流感病毒感染的临床特征。
N Engl J Med. 2013 Jun 13;368(24):2277-85. doi: 10.1056/NEJMoa1305584. Epub 2013 May 22.
6
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).2008-2011 年神经氨酸酶抑制剂耐药性的全球评估:流感耐药信息研究(IRIS)。
Clin Infect Dis. 2013 May;56(9):1197-205. doi: 10.1093/cid/cis1220. Epub 2013 Jan 10.
7
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.2010-2011 年美国耐奥司他韦的大流行性(H1N1)2009 病毒感染。
Emerg Infect Dis. 2012 Feb;18(2):308-11. doi: 10.3201/eid1802.111466.
8
Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.静脉滴注帕拉米韦治疗儿童 2009 年甲型 H1N1 流感病毒感染的疗效、安全性和药代动力学。
Antimicrob Agents Chemother. 2012 Jan;56(1):369-77. doi: 10.1128/AAC.00132-11. Epub 2011 Oct 24.
9
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.一项比较单剂量静脉滴注帕拉米韦与口服奥司他韦治疗季节性流感病毒感染患者的 III 期随机、双盲研究。
Antimicrob Agents Chemother. 2011 Nov;55(11):5267-76. doi: 10.1128/AAC.00360-11. Epub 2011 Aug 8.
10
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.半衰期对数学模型描绘扎那米韦抗流感病毒药效指标的影响。
Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53. doi: 10.1128/AAC.01629-10. Epub 2011 Jan 24.